Cargando…
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options. Recently, we have established a clinically relevant murine HCC model by co-expressing activated forms of v-akt murine thymoma vi...
Autores principales: | Liu, Xianqiong, Hu, Junjie, Song, Xinhua, Utpatel, Kirsten, Zhang, Yi, Wang, Pan, Lu, Xinjun, Zhang, Jie, Xu, Meng, Su, Tao, Che, Li, Wang, Jingxiao, Evert, Matthias, Calvisi, Diego F., Chen, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679026/ https://www.ncbi.nlm.nih.gov/pubmed/31277283 http://dx.doi.org/10.3390/cancers11070930 |
Ejemplares similares
-
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021) -
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018) -
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
por: Wang, Pan, et al.
Publicado: (2019) -
Oncogene-dependent function of BRG1 in hepatocarcinogenesis
por: Wang, Pan, et al.
Publicado: (2020) -
Early Subcellular Hepatocellular Alterations in Mice Post Hydrodynamic Transfection: An Explorative Study
por: Yasser, Mohd, et al.
Publicado: (2023)